Área: Biblioteca del área

CYP2D6 variation, behaviour and psychopathology:Implications for pharmacogenomics-guided clinical trials. Br J Clin Pharmacol. 2013 Aug 22.

Clinical characteristics and mortality of heart failure. INCAex study. Rev Clin Esp. 2013 Jan-Feb;213(1):16-24

CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics. 2013 Nov;23(11):627-30

Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain. Pharmacogenomics J. 2013 Aug 20

Impact of the CYP2D6 phenotype on the outcome of breast cancer patients treated with tamoxifen. Pharmacogenomics. 2013 Apr;14(6):606.

13C-dextromethophan breath test for phenotyping in breast cancer patients. Pharmacogenomics. 2013 Apr;14(6):605-6.

CYP2D6 genotypes and disease-freesurvival among women treated with tamoxifen. Pharmacogenomics. 2013 Apr;14(6):604-5.

Impact of cytochrome P450 genes on suicide attempt and risk. Eur Arch Psychiatry Clin Neurosci. 2013 Dec;263(8):703-4

Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6.Pharmacogenomics J. 2013 Oct;13(5):452-5

Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics J. 2013 Aug;13(4):359-61